Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.48 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20117984 | 1.00 | GAA (0.61) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL15131652 | 0.91 | GAA (0.52) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL2684956 | 0.89 | GAA (0.83) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL8041736 | 0.88 | GAA (0.74) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL2682570 | 0.85 | KMT2A (0.53) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL29435432 | 0.85 | MAPK1 (0.50) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL28674495 | 0.85 | GAA (0.58) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL29462964 | 0.85 | KMT2A (0.53) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL8827500 | 0.85 | MAPK1 (0.50) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL66639 | 0.85 | MAPK1 (0.50) | GAATDP1HTTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637715-B2 | Biomarkers and uses therefor | GenoDx Pty Ltd (AU) | 2026-05-26 | — | — | US | claimed |
| US-20250383354-A1 | LARGE ONCOSOME SURFACE PROTEINS FOR EARLY IDENTIFICATION OF CLINICALLY SIGNIFICANT PROSTATE CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2025-12-18 | — | — | US | claimed |
| US-20250316330-A1 | USE OF GENE COMBINATION IN PREPARATION OF HUMAN TUMOR HOMOLOGOUS RECOMBINATION DEFICIENCY, TUMOR MUTATION BURDEN AND MICROSATELLITE INSTABILITY GRADING DETECTION PRODUCTS | PEKING UNIVERSITY FIRST HOSPITAL (CN) | 2025-10-09 | — | — | US | claimed |
| WO-2025083257-A1 | METHODS FOR DETECTING APOPTOSIS | PROTEINERA HOLDING AB (SE) | 2025-04-24 | — | — | WO | claimed |
| WO-2025067873-A1 | SYNCHRONISATION AND CALIBRATION OF A DIGITAL TWIN BY MEANS OF HASH VALUES OF INTERVAL VALUES | SIEMENS AKTIENGESELLSCHAFT (DE) | 2025-04-03 | — | — | WO | claimed |
| US-20250101520-A1 | BIOMARKERS AND USES THEREFOR | GenoDx Pty Ltd (AU) | 2025-03-27 | — | — | US | claimed |
| US-20250084141-A1 | RNA ENCODING A THERAPEUTIC PROTEIN | CureVac SE (DE) | 2025-03-13 | — | — | US | claimed |
| EP-4512909-A1 | USE OF GENE COMBINATION IN PREPARATION OF HUMAN TUMOR HOMOLOGOUS RECOMBINATION DEFICIENCY, TUMOR MUTATION BURDEN AND MICROSATELLITE INSTABILITY GRADING DETECTION PRODUCTS | Peking University First Hospital (CN) | 2025-02-26 | — | — | EP | claimed |
| US-20240425925-A1 | BIOMARKERS AND USES THEREFOR | GenoDx Pty Ltd (AU) | 2024-12-26 | — | — | US | claimed |
| CN-117587128-B | Biomarker combinations and their use in predicting and/or diagnosing colorectal cancer | 上海爱谱蒂康生物科技有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-23 | — | — | US | claimed |
| WO-2023031427-A1 | DEVICE FOR CHARGING ELECTRICAL APPLIANCES, IN PARTICULAR ELECTRIC VEHICLES | CHARGEX GMBH (DE) | 2023-03-09 | — | — | WO | claimed |
| WO-2022271441-A1 | METHODS AND MATERIALS FOR TREATING CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-12-29 | — | — | WO | claimed |
| CN-113355422-B | Gene combination for human tumor classification and application thereof | 北京大学第一医院 | 2022-11-22 | — | — | CN | claimed |
| US-11485743-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | claimed |
| WO-2022184073-A1 | GENE COMBINATION FOR HUMAN TUMOR GRADING, AND USE THEREOF | 北京大学第一医院 | 2022-09-09 | — | — | WO | claimed |
| CN-114854861-A | Application of gene combination in preparation of human tumor homologous recombination defect, tumor mutation load and microsatellite instability grading detection product | 北京大学第一医院 | 2022-08-05 | — | — | CN | claimed |
| EP-3969483-A1 | ULTRASPECIFIC CELL TARGETING USING DE NOVO DESIGNED CO-LOCALIZATION DEPENDENT PROTEIN SWITCHES | University of Washington (US) | 2022-03-23 | — | — | EP | claimed |
| WO-2022051254-A2 | TARGET FOR MODULATING BODY MASS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022032070-A1 | PREDICTIVE UNIVERSAL SIGNATURES FOR MULTIPLE DISEASE INDICATIONS | Vir Biotechnology, Inc. (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485743-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GAA 269/4885TDP1 1654/4885HTT 86/4885 |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | GAA 269/4885TDP1 1654/4885HTT 86/4885 |
| US-12637715-B2 | Biomarkers and uses therefor | POLR2B, POLB, POLG | GAA 4036/4885TDP1 574/4885HTT 1478/4885 |
| US-20250084141-A1 | RNA ENCODING A THERAPEUTIC PROTEIN | NSUN3, SARNP, TRDMT1 | GAA 938/4885TDP1 1129/4885HTT 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.